← Back to Search

Cancer Vaccine

Core-g28v2 60mer mRNA Vaccine for HIV (Human Immunodeficiency Virus)

Phase 1
Waitlist Available
Research Sponsored by International AIDS Vaccine Initiative
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 months
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of two different vaccines for HIV-1 in adults who do not have the virus.

Who is the study for?
Healthy adults aged 18-51, willing to use effective contraception and undergo HIV testing. Excludes those with HIV, recent vaccinations or blood products, certain medication use, pregnancy/lactation plans within study period, bleeding disorders, significant infections or conditions like autoimmune diseases.Check my eligibility
What is being tested?
The trial is evaluating two experimental mRNA vaccines for HIV prevention: eOD-GT8 60mer (mRNA-1644) and Core-g28v2 60mer (mRNA-1644v2-Core). It's a first-in-human study assessing the safety and immune response in participants who receive these vaccines.See study design
What are the potential side effects?
Potential side effects are not detailed but may include typical vaccine reactions such as soreness at injection site, fever, fatigue or allergic reactions. Serious side effects could occur but are monitored closely due to the trial being in Phase 1.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Secondary outcome measures
Immunogenicity
Other outcome measures
Exploratory Immunogenicity

Trial Design

4Treatment groups
Experimental Treatment
Group I: Study Group 4Experimental Treatment1 Intervention
Core-g28v2 60mer mRNA Vaccine (100µg)
Group II: Study Group 3Experimental Treatment2 Interventions
eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
Group III: Study Group 2Experimental Treatment2 Interventions
eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
Group IV: Study Group 1Experimental Treatment1 Intervention
eOD-GT8 60mer mRNA Vaccine (100µg)

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

UT Health San AntonioUNKNOWN
ModernaTX, Inc.Industry Sponsor
108 Previous Clinical Trials
61,379,857 Total Patients Enrolled
The University of Texas at San AntonioOTHER
22 Previous Clinical Trials
7,448 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are my criteria suitable for acceptance into this research program?

"This medical trial is seeking 56 HIV-positive individuals between 18 and 50 years old. To be considered for the study, participants must use hormonal contraception (e.g., contraceptive implant or injectable), consent to comply with all protocol requirements and follow-up procedures, and practice safe sex by using condoms with or without spermicide."

Answered by AI

To what degree are elderly patients being included in the trial's participant demographics?

"According to the official criteria for inclusion, participants must be between 18 and 50 years old. There are 21 trials involving those younger than 18 and 61 studies with patients that exceed 65 years in age."

Answered by AI

Is enrollment in this trial still a viable opportunity for interested participants?

"According to the information on clinicaltrials.gov, this medical trial is not currently recruiting patients. The original post date was November 12th 2021 and it has been recently updated as of September 22nd 2022. This particular study may be closed to new candidates at present but there are still 83 other trials searching for participants right now."

Answered by AI

How many venues are offering this scientific exploration?

"5 medical sites across Atlanta, Seattle and Washington are presently recruiting patients for this trial. To reduce the need to travel, it is practical to select a clinic that is local or closeby."

Answered by AI

What risks accompany the administration of Core-g28v2 60mer mRNA Vaccine?

"Clinical evidence for the safety and efficacy of Core-g28v2 60mer mRNA Vaccine is still limited, resulting in a score of 1."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
2021. "A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05001373.
~16 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top